These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
24. Genetic medicine at the RNA level: modifications of the genetic repertoire for therapeutic purposes by pre-mRNA trans-splicing. Pergolizzi RG; Crystal RG C R Biol; 2004 Aug; 327(8):695-709. PubMed ID: 15506518 [TBL] [Abstract][Full Text] [Related]
25. Nanoscale platforms for messenger RNA delivery. Li B; Zhang X; Dong Y Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2019 Mar; 11(2):e1530. PubMed ID: 29726120 [TBL] [Abstract][Full Text] [Related]
26. Augmenting PBGD expression in the liver as a novel gene therapy for acute intermittent porphyria (AIPgene). Hum Gene Ther Clin Dev; 2014 Jun; 25(2):61-3. PubMed ID: 24933563 [No Abstract] [Full Text] [Related]
33. Porphyrias: animal models and prospects for cellular and gene therapy. de Verneuil H; Ged C; Boulechfar S; Moreau-Gaudry F J Bioenerg Biomembr; 1995 Apr; 27(2):239-48. PubMed ID: 7592571 [TBL] [Abstract][Full Text] [Related]
34. Adenoviral-mediated expression of porphobilinogen deaminase in liver restores the metabolic defect in a mouse model of acute intermittent porphyria. Johansson A; Nowak G; Möller C; Blomberg P; Harper P Mol Ther; 2004 Aug; 10(2):337-43. PubMed ID: 15294180 [TBL] [Abstract][Full Text] [Related]